Search results
Sep 13, 2021 · AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”. Three IBD clinical indications, including ulcerative colitis and Crohn’s disease ...
Mar 14, 2024 · First Wave BioPharma, Inc. Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease. James Sapirstein, Chairman and Chief Executive Officer, to...
Discover real-time First Wave BioPharma, Inc. Common Stock (FWBI) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with...
Dec 18, 2023 · Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline.
Sep 14, 2023 · First Wave to develop and repurpose Capeserod for gastrointestinal (GI) indications based on AI-empowered analyses, expanding the company’s GI-focused pipeline.
May 16, 2024 · The Company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease...
Feb 3, 2022 · First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
